Cudetaxestat
(Lung Fibrosis)
Phase 2
Ready
Revolutionizing the treatment of fibrotic & neurodegenerative diseases
Revolutionizing the treatment of fibrotic & neurodegenerative diseases
Revolutionizing the treatment of fibrotic & neurodegenerative diseases
Pipeline
We are positioned to build a pipeline across a range of fibrotic and neurodegenerative diseases.
BLD-2184
(Neurodegeneration)
IND Ready
BLD-3051
(Lung Fibrosis, Liver Fibrosis)
Pre-Clinical
Join our team
We are looking for people with the passion and commitment of the values we live by.
Passion and commitment to our mission
Accountability to the team
Integrity in everything we do
Be fearless
Recent News
September 20, 2021
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
Event
There are no events currently scheduled.
Bringing life changing and revolutionary treatments to patients with fibrotic and neurodegenerative diseases.